Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase 1 Terminated
28 enrolled
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
GVAX Plus Checkpoint Blockade in Neuroblastoma
Phase 1 Terminated
19 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Phase 1 Terminated
6 enrolled
PRIMO
Phase 1 Terminated
25 enrolled
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Phase 1 Terminated
11 enrolled
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase 1 Terminated
1 enrolled
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Phase 1 Terminated
9 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Phase 1 Terminated
22 enrolled 14 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
5 enrolled
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Phase 1 Terminated
2 enrolled 14 charts
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase 1 Terminated
6 enrolled
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase 1 Terminated
6 enrolled
CheckMate 76U
Phase 1 Terminated
21 enrolled
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase 1 Terminated
8 enrolled 16 charts
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
Phase 1 Terminated
5 enrolled 12 charts
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Phase 1 Terminated
82 enrolled
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
15 enrolled
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Phase 1 Terminated
47 enrolled
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Phase 1 Terminated
3 enrolled
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
Phase 1 Terminated
14 enrolled
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase 1 Terminated
6 enrolled
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Phase 1 Terminated
22 enrolled
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Phase 1 Terminated
3 enrolled
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Phase 1 Terminated
11 enrolled
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
Phase 1 Terminated
26 enrolled
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Phase 1 Terminated
19 enrolled
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Phase 1 Terminated
3 enrolled
SRS (Stereotactic Radiosurgery) Plus Ipilimumab
Phase 1 Terminated
4 enrolled
Mel-Ipi-Rx
Phase 1 Terminated
19 enrolled
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Phase 1 Terminated
18 enrolled 9 charts
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Phase 1 Terminated
28 enrolled